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Abstract
Background: Intraoperative electron radiotherapy (IOERT) is a highly selective radiotherapy technique which aims
to treat restricted anatomic volumes during oncological surgery and is now the subject of intense re-evaluation. In
vivo dosimetry has been recommended for IOERT and has been identified as a risk-reduction intervention in the
context of an IOERT risk analysis. Despite reports of fruitful experiences, information about in vivo dosimetry in
intraoperative radiotherapy is somewhat scarce. Therefore, the aim of this paper is to report our experience in
developing a program of in vivo dosimetry for IOERT, from both multidisciplinary and practical approaches, in a
consistent patient series. We also report several current weaknesses.
Methods: Reinforced TN-502RDM-H mobile metal oxide semiconductor field effect transistors (MOSFETs) and
Gafchromic MD-55-2 films were used as a redundant in vivo treatment verification system with an Elekta
Precise fixed linear accelerator for calibrations and treatments. In vivo dosimetry was performed in 45 patients
in cases involving primary tumors or relapses. The most frequent primary tumors were breast (37 %) and
colorectal (29 %), and local recurrences among relapses was 83 %. We made 50 attempts to measure with
MOSFETs and 48 attempts to measure with films in the treatment zones. The surgical team placed both
detectors with supervision from the radiation oncologist and following their instructions.
Results: The program was considered an overall success by the different professionals involved. The absorbed doses
measured with MOSFETs and films were 93.8 ± 6.7 % and 97.9 ± 9.0 % (mean ± SD) respectively using a scale in which
90 % is the prescribed dose and 100 % is the maximum absorbed dose delivered by the beam. However, in 10 % of
cases we experienced dosimetric problems due to detector misalignment, a situation which might be avoided with
additional checks. The useful MOSFET lifetime length and the film sterilization procedure should also be controlled.
Conclusions: It is feasible to establish an in vivo dosimetry program for a wide set of locations treated with
IOERT using a multidisciplinary approach according to the skills of the professionals present and the detectors
used; oncological surgeons’ commitment is key to success in this context. Films are more unstable and show
higher uncertainty than MOSFETs but are cheaper and are useful and convenient if real-time treatment
monitoring is not necessary.
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Background
Intraoperative electron radiotherapy (IOERT) is a highly
selective radiotherapy technique used to treat restricted
anatomical volumes during oncological surgery. Single-
fraction irradiation with a high absorbed-dose is deliv-
ered by means of an electron beam, after direct visual
examination of the tumor bed or non-resectable tumor
[1]. It allows the biological effect of ionizing radiation to
be maximized while minimizing or avoiding exposure to
adjacent at-risk organs. This technique is potentially
beneficial because it shortens the treatment time re-
quired compared to conventional fractionation, and it
does not interfere with the administration of systemic
therapy [2].
IOERT is currently the subject of intense review [3–5].
Therefore, in this context it is pertinent to also re-assess
in vivo dosimetry, which is generally recommended for
end-to-end tests [6] and to assess treatment verifications
[7], particularly for IOERT [8] where it has been identi-
fied as a risk-reduction intervention in the context of an
IOERT risk analysis [9].
Fruitful experiences based either on metal oxide semi-
conductor field effect transistors (MOSFETs) [10–12],
radiochromic films [13, 14], or both [15] have been re-
ported. However, information about in vivo dosimetry in
intraoperative radiotherapy is somewhat scarce. There-
fore, the aim of this paper is to report our experience in
developing a program of in vivo dosimetry for IOERT,
from both multidisciplinary and practical approaches, in
a consistent patient series.
Methods
Dosimetric equipment
Reinforced TN-502RDM-H mobile MOSFETs (Best
Medical Canada Ltd., Ontario, Canada) and Gafchromic
MD-55-2 film (International Specialty Products, NJ,
USA) were used as a redundant in vivo treatment verifi-
cation system. The absorbed doses used in the calibra-
tion procedure were accurately measured by a medical
physicist using routine dosimetric equipment following
the International Atomic Energy Agency’s TRS-398
protocol [16] immediately before irradiating the dosime-
ters. MOSFETs were read by selecting the standard sen-
sitivity bias setting [17]. A third-order polynomial
relationship between pixel value, read in the red channel,
and absorbed dose was used to calibrate the film. Films,
cut into 1.5 cm × 1.5 cm pieces, were read by an Epson
perfection V700 Photo flatbed digitizer (Seiko Epson
Corporation, Nagano, Japan). An Elekta Precise fixed lin-
ear accelerator (linac; Elekta AB, Stockholm, Sweden)
was used both for calibrations and treatments. The linac
is equipped with dedicated trays, capable of allocating
cylindrical applicators of 3, 4, 5, 6, 7, 8, 9, 10, 12, and
15 cm in diameter and 5 mm in thickness, made of
polycarbonate (MCP Iberia S.A., Madrid, Spain). All of
them have interchangeable distal ends with no bevel, a
30°-bevel, and a 45°-bevel which result in a nominal
source-to-applicator-end distance of 135 cm. The table
used for treatments was a SU-14 movable operating
table equipped with 150 mm diameter wheels with one
directional wheel (Famed Żywiec Sp. z o. o., Żywiec,
Poland).
Patients and measurements
We performed in vivo dosimetry in 45 patients from
March 2011 to January 2014 in cases involving primary
tumors (60 %) or relapses (40 %). Detectors were placed
in a variety of sites which are classified as depicted in
Fig. 1. The most frequently treated primary tumors were
breast (37 %) and colorectal (29 %), and the predomin-
ance of local recurrences among relapses was 83 %. Fifty
attempts to measure with MOSFETs and 48 attempts to
measure with films were made in the treatment zones.
The number of attempts was greater than the number of
patients because radiation oncologists documented other
measurements in the tumor bed for a few initial cases.
In addition to this, an extra film was not available for
the in vivo procedure in a couple of measurements of
this kind. However, for the purpose of completeness,
below we analyze all the valid readouts obtained. In 35
cases we were able to simultaneously measure with a
MOSFET and a film. These measurements were carefully
examined along with their setup to identify any anomal-
ous events. Afterward, we assessed the outliers of the
remaining data, which were defined as measurements
exceeding three standard deviations (SDs) of the sample
means, and were considered not to be representative of
the dose delivered to the tumor bed.
Surgical aspects
The surgical team placed the MOSFETs and radiochro-
mic films with supervision by the radiation oncologist
and following their instructions. The standard placement
was: one MOSFET and one radiochromic film at the
center and another optional MOSFET at the periphery
of the radiation field but out of the penumbral zone. As
the team gained confidence the detectors were restricted
to one MOSFET per patient because of economic fac-
tors. MOSFETs were always fixed to the radiation field
by two stitches in order to avoid it moving during the
procedure. When the surgical field was not horizontal
(i.e. in the vertical presacral field), the radiochromic film
was also fixed with stitches.
Ethical statement
This research was approved by our institution’s ethics
committee in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later
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amendments. Written informed consent for this proced-
ure was obtained from every patient.
Results
The program was considered an overall success as evalu-
ated by the different professionals involved. The time
between exiting the operating room (OR) and adminis-
tration of the radiation treatment was around 40 min,
which differed slightly according to the tumor location.
The irradiation parameters used and dosimetric results
obtained are shown in Table 1.
Of the 50 attempts to measure with a MOSFET, in 5
cases the detector could not be correctly attached to the
tumor bed meaning that movements during the treat-
ment setup pushed it towards or beyond the field limit,
therefore causing low dose measurement. This happened
specifically in 3 out of the 5 cases in which we placed
the optional MOSFET. In the other 45 cases the detector
Fig. 1 Distribution of neoplasms according to treatment intention and type
Table 1 Distribution of dosimetric parameters, f stands for their relative frequency
Applicator
diameter (cm)
f Energy
(MeV)
f Bevel
angle (°)
f Prescribed
dose (Gy)
f
4 4 % 4 6 % 0 56 % 5 6 %
5 2 % 6 17 % 30 33 % 9 8 %
6 35 % 9 52 % 45 10 % 10 8 %
7 23 % 12 19 % 12 4 %
8 13 % 15 6 % 12.5 33 %
9 13 % 15 17 %
10 6 % 17 4 %
12 4 % 17.5 6 %
21 13 %
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was able to measure the absorbed dose delivered to the
tumor bed. However, 3 of these 45 measurements were
affected by backscattering caused by the lead protector
(which is required in some cases [18]) placed next to the
detector, resulting in measurements that were higher
than expected in the region (in 1 case out of the 5 op-
tional MOSFETs), and 2 recorded an anomalous low
reading (less than three SDs from the sample mean).
The descriptive statistics of the remaining 40 measure-
ments, which were assessed as valid, are presented in
Table 2 and their distribution is depicted in Fig. 2. The
only valid measurement taken by an optional MOSFET
differed by −6.4 % compared to the absorbed dose from
the MOSFET placed in the center of the tumor bed.
With regard to films, it is worth mentioning that in
two cases the detector was severely damaged at an un-
known point during the procedure and a readout could
not be obtained. With respect to the 46 attempts to
measure with a valid film, in four cases the detector
could not be correctly attached to the tumor bed, and
movements during treatment setup pushed it out of the
field or lifted it so that the film was incorrectly irradiated
at an angle very far from perpendicular. The descriptive
statistics of the remaining 42 measurements, which were
assessed as valid, are also presented in Table 2. Their
distribution is shown in Fig. 2.
After discarding anomalous data affected by the fac-
tors mentioned above, a total of 30 paired measurements
from the tumor bed were obtained; their descriptive sta-
tistics are represented in Table 3.
Discussion
Calibration issues
As suggested by Agostinelli et al. [12], we calibrated
every MOSFET, and based on the energy used. Our cali-
bration factors (CFs) ranged from 97.1 to 104.5 mV/Gy,
with a mean of 101.2 mV/Gy. They reported a similar
result with a mean CF of 105 mV/Gy [12]. The mean re-
producibility of our CFs in terms of the mean relative
SD was 1.5 % which is very close to the 2 % obtained
also by Agostinelli et al. [12] and Bloemen-van Gurp et
al. [17]. The CF variability leads us to recommend per-
forming a different MOSFET calibration for every energy
used. Nonetheless, the calibration factors obtained under
specific circumstances can be very similar, which has
motivated the use of only some energies [19]. In con-
trast, the film readout is independent of the therapy
beam energies [20]. A session which measures both the
dose delivered by the linac and the calibration of one of
the detectors spends approximately 1 h of linac time and
so it is not as time consuming. In the case of films, the
user should also consider both hardware and software
needs. As a minimum a flatbed digitizer and image pro-
cessing software capable of splitting the signals from dif-
ferent channels and evaluating statistical data inside
defined regions of interest [21] should be used. More-
over, the direct use of net red pixel values to fit the film
calibration curve (r2 > 0.999) is as satisfactory as the use
of optical densities [22, 23].
Surgical procedure and detector handling
Despite the surgical team’s effort to obtain proper and
reliable sensor placement, dosimetry failed in around
10 % of cases, presumably because of unintended de-
tector movements and misalignment. We experienced
the latter problem when we tried to measure using two
MOSFETs at the same time, as reported in the results
section. The difficulty of inserting more than one MOS-
FET has also been identified elsewhere [24]. In addition,
it has been pointed out that MOSFETs are presumably
more difficult for the surgeon to initially handle because
they have to be inserted with sterile components and at-
tached onto the surgical bed [15]. Moreover, the com-
pression placed on the MOSFET by the applicator can
also move it [10]. However, we did not find any relation-
ship between particular surgeons or difficulty of access
to the surgical bed in these affected cases, and so we rec-
ommend that double-checking the detector placement
before irradiation may reduce this problem in some
cases.
Given the above circumstances, after treating the first
23 patients, measurements were performed only in the
center of the tumor bed, when the team had gained con-
fidence with respect to measurements in that zone, and
thus we considered the learning curve to be surpassed.
This decision implied savings in the cost of MOSFETs
and catheters.
Backscattering might be addressed by adding bolus
cut-outs to the lead protectors, however, the surgical
team should evaluate the feasibility of this solution
(which involves intensive handling of external pieces on
the tumor bed) before it is routinely implemented.
In one case the MOSFET was depleted during the
treatment and therefore subsequent readout was not
possible. To avoid this pitfall, we recommended that the
Table 2 Descriptive statistics of the valid measurements: 40
measurements taken with MOSFETs and 42 measurements
taken with films
% Absorbed dose MOSFET Film
Minimum 78.0 72.0
1st quartile 90.0 92.7
Median 92.8 98.1
2nd quartile 97.9 103.1
Maximum 111.6 123.4
Mean 93.8 97.9
Standard deviation 6.7 9.0
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dosimeter gate voltage be read before the treatment is
administered. We presume that film damage occurred
during sterilization, indicating that the stability of the
sterilization procedure should also be checked.
The detectors were attached in the OR before patient
transportation and while the linac bunker was being pre-
pared for the irradiation. This is why in vivo dosimetry
only took 5 min more, representing the time spent veri-
fying the detector placement just before patient
treatment.
The impact of using a fixed linear accelerator
When IOERT was first introduced into medicine it was
performed by using conventional linacs in the radiother-
apy treatment vaults [1]. However, in the 1990s, dedi-
cated mobile linacs, characterized by output rates of 2 to
12 cGy per pulse, were developed and introduced [4].
The high dose-per-pulse reduces the irradiation time
during the surgery because 10 Gy are typically delivered
in less than 1 min [24].
Non-exclusive fixed linacs offer several advantages
over the mobile ones as they allow verification of proper
alignment between the treatment field and the collima-
tor: a so-called pseudo-guided image [25]. In addition,
they supply a wide range of energies that provide better
coverage in response to the thickness of the target vol-
ume. The stability of their output is also better, with
day-to-day variations equal to or less than 0.4 %, i.e. 1
SD [26]. This is one order of magnitude less than the
output stability of mobile linacs [12]. Nevertheless, fixed
linacs require more infrastructure, i.e. a more complex
organizational system which is specifically designed for
development of the procedure. They also require high-
level cooperation between staff and a larger multidiscip-
linary team. This is why it is advisable to design detailed
protocols conforming to clinical indications, as well
planning the whole process in detail.
Despite these disparities between mobile and fixed
linacs, in vivo dosimetry seems to perform equally well
for both kinds of treatment machines [10, 11, 13, 15]. In
contrast, using a mobile linac does not ensure that low
variability is achieved with respect to in vivo dosimetry
results, as discussed below [12].
Dosimetry
The central values of all the distributions presented laid
inside the range limited by the prescribed dose to the
tumor bed in our institution (90 %) and the maximum
absorbed dose (100 %). However, the spread of our mea-
surements were wider than those reported in the litera-
ture, which ranged from 17.6 % [11] to 21.2 % [27]. This
may have been influenced by the wide set of tumor loca-
tions treated, each with different degrees of complexity.
Besides, our series of cases included 40 % relapses, which
may involve areas already irradiated with conformal radio-
therapy and/or affected by a prior surgery. These interven-
tions favor the appearance of fibrosis [28, 29] which
retracts tissues and may make dosimeter placement diffi-
cult. In the case of MOSFETs, if the maximum and mini-
mum values are omitted, the resulting range is 23.8 %
which is comparable to the results mentioned above. In
this context, the work by Agostinelli et al. [12] illustrates
how the range of differences between the MOSFET dose
Fig. 2 Histograms of measured absorbed doses classified by the type of detector
Table 3 Descriptive statistics of the paired measurements
% Absorbed dose MOSFET Film
Minimum 78.0 72.0
1st quartile 90.2 92.4
Median 92.5 97.3
2nd quartile 97.6 103.0
Maximum 111.6 123.4
Mean 93.9 97.9
Standard deviation 6.8 9.7
Thirty pairs of values for which the prescribed dose was 90 % and the maximum
absorbed dose delivered was 100 %
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and the expected dose can be as much as 43 % even when
using a single mobile machine to treat only breast tumor
beds, and describes how they had to develop
normalization tools to better correlate these doses. Fur-
thermore, the need for increased precision has been re-
ported elsewhere [30], although future imaging tools
which are still in research and development may improve
this issue [31].
Film measurements were more wide-ranging and
tended to diverge from MOSFET measurements over
time. In fact both samples were shifted to a near-
significant degree (p = 0.070) which was presumably
caused by long-term film instability. In addition, radio-
chromic film exhibited a greater uncertainty caused by a
higher intrinsic response variation compared to MOS-
FET readout reproducibility. These factors do not im-
pede dosimetry but users should be aware that they
should control film response in a more intensive way
than for MOSFET measurements.
Economic factors
With regard to consumable costs, we spent over $135
per patient with MOSFET dosimetry and $2 per patient
with film dosimetry (according to our institution coun-
try’s prices in December 2014). The calibration process
can be easily allocated within the linac quality control
sessions and so does not directly incur additional costs.
The MOSFET reading equipment is more expensive
than the hardware required to read films, but it can be
also used to perform in vivo dosimetry for other radio-
therapy techniques. The cost of a flatbed scanner is in-
corporated into the departmental costs as it is also used
to scan documents in the department, and the
sterilization costs form part of the general sterilization
activities in the hospital. Finally, free access image ana-
lysis software like ImageJ (National Institutes of Health,
MD, USA) is available on the internet. Unfortunately, to
the knowledge of the authors, there are no other reports
on these costs available. This information would also
help new users to decide on the best dosimetric mate-
rials to use.
Conclusions
It is feasible to establish an in vivo dosimetry pro-
gram for a wide set of locations treated with IOERT.
This program should present a multidisciplinary ap-
proach according to the skills of the professionals
implementing it and with regard to the detectors in
use. The commitment of oncological surgeons is key
to its success because they are the professionals who
are authorized to intervene in patient tumor beds and
they are largely responsible for detector positioning.
Films are more unstable and suffer from a higher un-
certainty than MOSFETs, but they are also useful and
convenient if treatment monitoring in real-time is not
required.
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